NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) announced today that the tender offer, through its wholly owned subsidiary Zeus Acquisition Corporation, for all outstanding shares of common stock of ZymoGenetics, Inc. (NASDAQ: ZGEN) expired at midnight New York City time on October 7, 2010, and was not extended.
